Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Oct 29;154(12):4580–4593. doi: 10.1210/en.2013-1613

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 by The Endocrine Society

This article has been published under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s). Author(s) grant(s) the Endocrine Society the exclusive right to publish the article and identify itself as the original publisher.

PMC Copyright notice

Figure 6. — Body weight and food intake effects of a higher dose of the 11β-HSD1 inhibitor, MK-0916, are “off target.” A and B, Body weight change in WT (A) and GKO (B) mice with 30 mg/kg/d MK-0916 treatment. □, vehicle-treated WT; ■, 30 mg/kg/d MK-0916–treated WT; ○, vehicle-treated GKO; ●, 30 mg/kg/d MK-0916–treated GKO. C, Percentage body weight change on day 21. D, Cumulative food intake during the 22-day treatment. E, Fasting glucose levels on treatment day 16. F, Insulin resistance as measured by HOMA-IR at treatment day 16. Data are expressed as means ± SEM; n = 6 to 8. **, P < .01; ***, P < .001 vs vehicle treatment for that genotype.